Tyr-c[D-Orn-Tyr(Bzl)-Pro-Gly]: A novel antiproliferative acting somatostatin receptor agonist with μ-opioid receptor-sensitizing properties

British Journal of Pharmacology

Volumn 140, Issue 1, 2003, Pages 13-22

  Stirnweiss, Jörg ^a   Hartrodt, Bianka ^b   Greksch, Gisela ^c   Stürzebecher, Uta ^a   Böhmer, Frank D ^a   Neubert, Klaus ^b   Liebmann, Claus ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

receptor sensitization; Cell growth inhibition; Cyclopeptide; SH SY5Y cells; SSTR1 receptors

Indexed keywords

BETA CASOMORPHINE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPEPTIDE; DELTA OPIATE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; KAPPA OPIATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MORPHINE; MU OPIATE RECEPTOR; OPIATE DERIVATIVE; PROTEIN P21; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN COS7; CELL TYPE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; RECEPTOR AFFINITY; RECEPTOR SENSITIVITY; STIMULATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDORPHINS; GROWTH INHIBITORS; HUMANS; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; PEPTIDE FRAGMENTS; RECEPTORS, OPIOID, MU; RECEPTORS, SOMATOSTATIN;

EID: 0141730394     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705416     Document Type: Article

References (27)

1. CHENG, J., STANDIFER, K.M., TUBLIN, P.R., SU, W. & PASTERNAK, G.W. (1995). Demonstration of kappa 3-opioid receptors in the SH-SY5Y human neuroblastoma cell line. J. Neurochem., 65, 170-175.
2. 2 receptor coupling to mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells. Br. J. Pharmacol., 120, 455-463.
3. COX, B.M., GINSBURG, M. & OSMAN, O.H. (1968). Acute tolerance to narcotic analgesic drugs in rats. Br. J. Pharmacol., 33, 245-256.
4. FLORIO, T., THELLUNG, S., ARENA, S., CORSARO, A., BAJETZTO, A., SCHETTINI, G. & STORK, P.J. (2000). Somatostatin receptor 1 (SSTR1) -mediated inhibition of cell proliferation correlates with the activation of MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J. Physiol. (Paris), 94, 239-250.
5. FLORIO, T., YAO, N., CAREY, K.D., DILLON, T.J. & STORK, P.J. (1999). Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1(SSTR1). Mol. Endocrinol., 13, 24-37.
6. GRANESS, A., HANKE, H., BOEHMER, F.-D., PRESEK, P. & LIEBMANN, C. (2000). Protein-tyrosine-phosphatase-mediated epidermal growth factor (EGF) receptor transinactivation and EGF receptor-independent stimulation of mitogen-activated protein kinase by bradykinin in A431 cells. Biochem. J., 347, 441-447.
7. GREKSCH, G., SCHWEIGERT, C.H. & MATTHIES, H. (1981). Evidence for analgesic activity of β-casomorphin in rats. Neurosci. Lett., 27, 325-328.
8. GUTKIND, J.S. (1998). The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J. Biol. Chem., 273, 159-161.
9. HATZOGLOU, A., BAKAGEORGOU, E., HATZOGLOU, C., MARTIN, P.M. & CASTANAS, E. (1996). Antiproliferative and receptor binding properties of alpha- and beta-casomorphins in the T47D human breast cancer cell line. Eur. J. Pharmacol., 310, 217-223.
10. HATZOGLOU, A., OUAFIK, L., BAKOGEOGOU, E., THERMOS, K. & CASTANAS, E. (1995). Morphine cross-reacts with somatostatin receptor SSTR2 in T47D human breast cancer cell line and decreases cell growth. Cancer Res., 55, 5632-5636.
11. HRUBY, V.J., HAN, G. & HADLEY, M.E. (1998). Design and bioactivities of melanotropic peptide agonists and antagonists: design based on a conformationally constrained somatostatin template. Lett. Pept. Sci., 5, 117-120.
12. JANECK, A., ZUBBRZYCKA, M. & JANECKI, T. (2001). Somatostatin analogs. J. Pept. Res., 58, 91-107.
13. KAMPA, M., BAKAGEORGOU, E., HATZOGLOU, A., DAMIANSKI, A., MARTIN, P.-M. & CASTANAS, E. (1997). Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur. J. Pharmacol., 335, 255-265.
14. KAMPA, M., LOUKAS, S., HATZOGLOU, A., MARTIN, P., MARTIN, P.-M. & CASTANAS, E. (1996). Identification of a novel opioid peptide (Tyr-Val-Pro-Phe-Pro) derived from human alpha S1 casein (alpha S1-casomorphin, and alpha S1-casomorphin amide). Biochem. J., 319, 903-908.
15. LIEBMANN, C. (2001). Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal., 13, 777-785.
16. LOPEZ, F., ESTEVE, J.P., BUSCAIL, L., DELESQUE, N., SAINT-LAURENT, N., THEVENIAU, M., NAHMIAS, C., VAYSSE, N. & SUSINI, C. (1997). The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. J. Biol. Chem., 272, 24448-24454.
17. LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
18. MANECKJEE, R., BISWAS, R. & VONDERHAAR, B. (1990). Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res., 50, 2234-2238.
19. MULDER, A.H., WARDEH, G., HOGENBOOM, F., KAZMIERSKI, W., HRUBY, V.J. & SCHOFFELMEER, A. (1991). Cyclic somatostatin analogues as potent antagonists at mu-, but not delta- and kappa-opioid receptors mediating presynaptic inhibition neurotransmitter release in the brain. Eur. J. Pharmacol., 205, 1-6.
20. ÖSTMAN, A. & BÖHMER, F.-D. (2001). Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell. Biol., 11, 258-266.
21. PAGES, P., BEKALI, N., SAINT-LAURENT, N., ESTEVE, J.P., SCHALLY, A.V., TKACZUK, J., VAYSSE, N., SUSINI, C. & BUSCAIL, L. (1999). Sst2 somatostatin receptor mediates cell cycle arrest and induction of 227 (Kip1). J. Biol. Chem., 274, 15186-15193.
22. PELTON, J.T., KAZMIERSKI, W., GULYA, K., YAMAMURA, H.I. & HRUBY, V.J. (1986). Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J. Med. Chem., 29, 2370-2375.
23. SCARPIGNATO, C. & PELOSINI, I. (2001). Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy, 47, 1-29.
24. SCHMIDT, R., NEUBERT, K., BARTH, A., LIEBMANN, C., SCHNITTLER, M., CHUNG, N.N. & SCHILLER, P.W. (1991). Structure-activity relationships of cyclic β-casomorphin-5 analogues. Peptides, 12, 1175-1180.
25. STETAK, A., LANKENAU, A., VANTUS, T., CSERMELY, P., ULLRICH, A. & KERI, G. (2001). The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-SRC. Biochem. Biophys. Res. Commun., 285, 483-488.
26. TOLL, L., POLGAR, W.E. & AUH, J.S. (1997). Characterization of the delta-opioid receptor found in SH-SY5Y neuroblastoma cells. Eur. J. Pharmacol., 323, 261-267.
27. WANG, Z. & SADEE, W. (2000). Tolerance to morphine at the mu-opioid receptor differentially induced by cAMP-dependent protein kinase activation and morphine. Eur. J. Pharmacol., 389, 165-171.